Expanding HER2 horizons: Implications for NSCLC and beyond

touchPANEL DISCUSSION for touchONCOLOGY Listen to three experts as they explore tissue-agnostic HER2 targeting in solid tumours, the latest clinical trial data for approved and emerging HER2-targeted therapies in NSCLC, and best practices for testing for HER2 alterations in NSCLC.   The experts Dr Razelle Kurzrock - Medical Oncologist, Medical College of Wisconsin, Milwaukee, WI, USA Dr Lyudmila Bazhenova - Medical Oncologist, UC San Diego Moores Cancer Center, San Diego, CA, USA Dr Ignacio Wistuba - Pathologist, MD Anderson Cancer Center, Houston, TX, USA This touchPODCAST is for HCPs outside of the UK only. This activity is funded by an independent medical education grant from AstraZeneca, and is jointly provided by USF Health and touchIME.  For further information visit our website: https://touchoncologyime.org/her2_in_solid_tumours_and_nsclc/